In dose/time experiments spanning 20–100 μM and 24–72 hours, hesperidin reduced MTT viability in HeLa and HT-29 cancer cells, with the strongest effects at higher concentrations and longer exposures. The 20 μM bars were not marked significant. The authors reported HeLa viability of 12% of control at 100 μM after 72 hours. MTT viability is distinct from an IC50 or evidence of cancer-cell selectivity. [1]
Hesperidin decreases MTT viability in HeLa and HT-29 cells
Cell-based study · Human HeLa cervical cancer and HT-29 colon cancer cell lines (ATCC) [1]
MTT signal declined with increasing concentration and exposure time relative to the 0 μM control. The reported 12% result is for HeLa at 100 μM after 72 h; no IC50 is supplied here. MTT is a metabolic viability endpoint rather than a direct proliferation count. The 20 μM bars are not marked statistically significant in Figure 1.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 20, 40, 60, 80 and 100 μM
- Exposure duration
- 24, 48 or 72 h
- Method
- Cell treatment followed by MTT assay; background from cell-free medium subtracted.
- Reported limits
- Treatment solvent and final treatment-vehicle concentration are not specified in the read Methods. DMSO used to dissolve MTT formazan is not evidence of treatment vehicle.
Methods and source locations
Compound reported in the paper: Hesperidin; Compound label in the paper: HES
Literature findings for hesperidin in the stated model; no Adooq product or lot performance validation.
Methods: Chemicals and reagents; Cell culture; MTT cell proliferation assay; Results: HES-induced morphological changes and anti-proliferation effect; Figure 1b,d
HeLa relative cell viability at 100 μM for 72 h: MTT; six wells per group; assay repeated three times; mean ± SEM is the stated reporting convention. — Results: HES-induced morphological changes and anti-proliferation effect (last paragraph); Figure 1b; Methods: MTT cell proliferation assay
Apoptosis-associated phenotype and ER stress markers in HeLa cells
Cell-based study · Human HeLa cervical cancer cells (ATCC) [1]
After 48 h, hesperidin was associated with condensed nuclei, DNA fragmentation and increased CHOP, GRP78 and cleaved caspase-3. These observations support an apoptosis-associated ER stress response; they do not establish a direct molecular target or prove ER stress is required for cell death.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 40, 80 and 160 μM
- Exposure duration
- 48 h
- Method
- Hoechst 33342 nuclear staining, DNA laddering and immunoblotting versus 0 μM cells.
- Reported limits
- Treatment vehicle is unspecified. No ER-pathway genetic perturbation or selective ER-stress rescue is demonstrated by these adopted experiments.
Methods and source locations
Compound reported in the paper: Hesperidin; Compound label in the paper: HES
Literature findings for hesperidin in the stated model; no Adooq product or lot performance validation.
Methods: apoptosis detection and Western blot analysis; Results: HES-induced apoptosis; DNA fragmentation; HES increased the levels of GADD153/CHOP...; Figures 2a,b, 3, 7
CHOP, GRP78 and cleaved caspase-3 abundance at 40 μM for 48 h versus control: Immunoblot; mean ± SEM of at least three experiments; Figure 7 denotes p < 0.05 versus 0 μM. Exact fold values are not adopted because cleaved caspase-3 differs between prose and the figure. — Figure 7 printed band ratios and caption; Methods: Western blot analysis
Nuclear condensation and DNA fragmentation: Hoechst staining and DNA gel electrophoresis; no exact apoptosis fractions extracted from plots. — Figures 2a,b and 3; corresponding Results paragraphs
Paraptosis-like cell death and ERK-associated modulation in HepG2 cells
Cell-based study · Human HepG2 cells from Korean Cell Line Bank [2]
At 1 mM, hesperidin produced cytoplasmic vacuoles and mitochondrial/ER swelling without typical apoptotic nuclear changes. Active caspase-3 and cleaved PARP were not detected, and z-VAD.fmk did not rescue MTT viability. U0126 reduced ERK phosphorylation and the vacuolated phenotype. The authors describe this as paraptosis-like death.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 mM hesperidin; DAPI series also includes 0.1 and 2 mM
- Exposure duration
- 24 h for immunoblots and caspase-inhibitor MTT; TEM at 24 and 48 h
- Method
- Vehicle-controlled cell treatment with ultrastructure, DNA gel, immunoblot and inhibitor controls.
- Vehicle
- 1% DMSO
- Co-treatment
- Mechanistic controls: z-VAD.fmk 20 μM for 1 h before hesperidin; U0126 10 μM for 2 h before hesperidin (not therapeutic combinations).
- Reported limits
- No direct hesperidin binding target or genetic ERK validation established. Negative caspase blots lack an apoptotic positive-control lane in the viewed Figure 5A.
Methods and source locations
Compound reported in the paper: Hesperidin; Compound label in the paper: hesperidin
Literature findings for hesperidin in the stated model; no Adooq product or lot performance validation.
Materials and Methods: Cell Culture and Treatment, Electron Microscopy, DNA Fragmentation, Western blot, Inhibitor assay; Results; Figures 3, 5A–B, 6
Apoptotic-marker and caspase-inhibitor assessment: Figure 5A immunoblot and 5B MTT; mean ± SD of three replicate independent experiments as captioned. No numerical rescue magnitude inferred. — Figure 5A–B and Results: Hesperidin induced cell death is caspase independent
ERK phosphorylation and vacuolated ultrastructure with U0126: Immunoblot with β-actin loading control; TEM. Pharmacological evidence supports involvement, not direct target inhibition by hesperidin. — Figure 6A–B; Figure 3B a–f; Results: Involvement of ERK1/2 MAPK in paraptosis